HIV Research Preview for ICAAC/ICC 2015
September 15, 2015
This year, the Interscience Conference of Antimicrobial Agents and Chemotherapy (ICAAC) joins forces with the International Congress of Chemotherapy and Infection (ICC) to present ICAAC/ICC 2015. Long conference name aside, this meeting starts on Sept. 17, and TheBodyPRO.com will be on-site to provide news and analysis on the latest HIV research. But before we get there, here's a look at what's noteworthy on the agenda.
One of the mainstays at almost every HIV conference is a look at our current progress in antiretroviral therapy and what we can expect going forward. This session should be interesting, as we're post-START study results, (which found that starting treatment immediately for all people living with HIV, regardless of CD4+ count, was more beneficial than delaying). The focus now shifts more to questions such as, "What to start?" and "When to switch?"
In addition -- even with 28 HIV drugs approved by the U.S. Food and Drug Administration (FDA) -- we'll get a look ahead at new antiretroviral drugs in the pipeline. In a presentation by Roy Gulick, M.D., we'll hear about drugs in development, both in current HIV drug classes and in new classes.
Prevention will continue to be a big theme, as we have seen growing focus on pre-exposure prophylaxis (PrEP) and treatment as prevention. With studies and real-world data showing overwhelming evidence that PrEP works, Kenneth Mayer, M.D., will discuss how to build on this foundation. Currently, PrEP is taken as an oral-based pill regimen. We'll get a glimpse at new ways of taking PrEP currently under study, including injectable medications, vaginal rings, rectal gels, films and douches containing antiretrovirals.
This session will get into some of the specifics of providing care for patients with HIV, particularly when challenges and complexities arise. We'll see presentations on identifying and treating acute HIV; managing complications in patients who have been living with HIV for a long time; and treating hepatitis C (HCV) coinfection and opportunistic infections.
Warren Tong is the senior science editor for TheBody.com and TheBodyPRO.com.
Follow Warren on Twitter: @WarrenAtTheBody.
This article was provided by TheBodyPRO. It is a part of the publication The 55th Interscience Conference on Antimicrobial Agents and Chemotherapy.
Add Your Comment:
(Please note: Your name and comment will be public, and may even show up in
Internet search results. Be careful when providing personal information! Before
adding your comment, please read TheBody.com's Comment Policy.)
The content on this page is free of advertiser influence and was produced by our editorial team. See our content and advertising policies.